Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial

AbstractThe aim of the present study was to investigate the effect of Bifidobacterium animalis subsp. lactis, BB-12®, on two primary end points – defecation frequency and gastrointestinal (GI) well-being – in healthy adults with low defecation frequency and abdominal discomfort. A total of 1248 subjects were included in a randomised, double-blind, placebo-controlled trial. After a 2-week run-in period, subjects were randomised to 1 or 10 billion colony-forming units/d of the probiotic strain BB-12® or a matching placebo capsule once daily for 4 weeks. Subjects completed a diary on bowel habits, relief of abdominal discomfort and symptoms. GI well-being, defined as global relief of abdominal discomfort, did not show significant differences. The OR for having a defecation frequency above baseline for ≥50 % of the time was 1·31 (95 % CI 0·98, 1·75), P=0·071, for probiotic treatment overall. Tightening the criteria for being a responder to an increase of ≥1 d/week for ≥50 % of the time resulted in an OR of 1·55 (95 % CI 1·22, 1·96), P=0·0003, for treatment overall. A treatment effect on average defecation frequency was found (P=0·0065), with the frequency being significantly higher compared with placebo at all weeks for probiotic treatment overall (all P<0·05). Effects on defecation frequency were similar for the two doses tested, suggesting that a ceiling effect was reached with the one billion dose. Overall, 4 weeks’ supplementation with the probiotic strain BB-12® resulted in a clinically relevant benefit on defecation frequency. The results suggest that consumption of BB-12® improves the GI health of individuals whose symptoms are not sufficiently severe to consult a doctor (ISRCTN18128385).

Download Full-text

Effect of Bifidobacterium animalis subsp. lactis MN-Gup on constipation and the composition of gut microbiota

Beneficial Microbes ◽

10.3920/bm2020.0023 ◽

2020 ◽

pp. 1-12

Author(s):

R. Wang ◽

J. Sun ◽

G. Li ◽

M. Zhang ◽

T. Niu ◽

...

Keyword(s):

Gut Microbiota ◽

Controlled Trial ◽

Functional Constipation ◽

Short Chain Fatty Acids ◽

Double Blind ◽

Double Blind Placebo ◽

Human Faeces ◽

Bifidobacterium Animalis ◽

Defecation Frequency ◽

Wet Weight

Probiotics have been reported to be associated with the alleviation of constipation. The aim of this study was to detect and determine the effect of Bifidobacterium animalis subsp. lactis MN-Gup (MN-Gup) on the alleviation of constipation in BALB/c mice and humans, and to elucidate the mechanisms underlying its effect by measuring changes in the concentration of short-chain fatty acids and the composition of microbes in human faeces. BALB/c mice were given MN-Gup by gavage for 14 days. On the 8th day of this treatment, constipation was induced by the application of diphenoxylate via gavage. The results showed that MN-Gup significantly decreased the first black stool defecation time, and significantly increased black faecal wet weight, black faecal number and the gastric-intestinal transit rate (P<0.05), thereby relieving constipation. In humans, a randomised, double-blind, placebo-controlled trial was performed to investigate the effect of MN-Gup in adults with functional constipation. After 4 weeks of intervention with placebo or MN-Gup yogurt, constipation-related symptoms (including defecation frequency, stool consistency, straining and incomplete feeling during defecation) in the constipated subjects were significantly improved in the two groups, but not different between the groups at the end of the intervention. The concentration of acetate increased significantly in the MN-Gup group compared to the placebo group and before ingestion. Significant changes in the composition of gut microbiota were found after intake of MN-Gup yogurt when compared to placebo. The relative abundances of acetate-producing Bifidobacterium, Ruminoccaceae_UCG-002 and Ruminoccaceae_UCG-005 were significantly increased after intake of MN-Gup yogurt. These results showed that MN-Gup could relieve constipation related to increased acetate-producing Bifidobacterium, Ruminoccaceae_UCG-002 and Ruminoccaceae_UCG-005.

Download Full-text

Probiotic treatment of collagenous colitis: A randomized, double-blind, placebo-controlled trial with Lactobacillus acidophilus and Bifidobacterium animalis subsp. Lactis

Inflammatory Bowel Diseases ◽

10.1097/01.mib.0000218763.99334.49 ◽

2006 ◽

Vol 12 (5) ◽

pp. 395-401 ◽

Cited By ~ 51

Author(s):

Signe Wildt ◽

Lars K. Munck ◽

Lars Vinter-Jensen ◽

Birgit Fischer Hanse ◽

Inge Nordgaard-Lassen ◽

...

Keyword(s):

Lactobacillus Acidophilus ◽

Controlled Trial ◽

Collagenous Colitis ◽

Double Blind ◽

Double Blind Placebo ◽

Bifidobacterium Animalis ◽

Probiotic Treatment

Download Full-text

A Double-Blind, Placebo Controlled-Trial of a Probiotic Strain Lactobacillus sakei Probio-65 for the Prevention of Canine Atopic Dermatitis

Journal of Microbiology and Biotechnology ◽

10.4014/jmb.1506.06065 ◽

2015 ◽

Vol 25 (11) ◽

pp. 1966-1969 ◽

Cited By ~ 14

Author(s):

Hyejin Kim ◽

Irfan A. Rather ◽

Hyunwook Kim ◽

Sungsoo Kim ◽

Taeeun Kim ◽

...

Keyword(s):

Atopic Dermatitis ◽

Controlled Trial ◽

Probiotic Strain ◽

Lactobacillus Sakei ◽

Double Blind ◽

Canine Atopic Dermatitis ◽

Double Blind Placebo

Download Full-text

The Effects of Probiotic Supplementation on Anthropometric Growth and Gut Microbiota Composition in Patients With Prader-Willi Syndrome: A Randomized Double-Blinded Placebo-Controlled Trial

Frontiers in Nutrition ◽

10.3389/fnut.2021.587974 ◽

2021 ◽

Vol 8 ◽

Author(s):

Xue-Jun Kong ◽

Guobin Wan ◽

Ruiyi Tian ◽

Siyu Liu ◽

Kevin Liu ◽

...

Keyword(s):

Gut Microbiome ◽

Therapeutic Potential ◽

Controlled Trial ◽

Genetic Disorder ◽

Prader Willi Syndrome ◽

Gut Health ◽

Double Blind ◽

Microbiome Composition ◽

Bifidobacterium Animalis ◽

Probiotic Treatment

Background: Prader-Willi Syndrome (PWS) is a rare genetic disorder associated with developmental delay, obesity, and neuropsychiatric comorbidities. Bifidobacterium animalis subsp. lactis has demonstrated anti-obesity and anti-inflammatory effects in previous studies.Aim: To evaluate the effects of Bifidobacterium animalis subsp. lactis probiotics supplementation on anthropometric growth, behavioral symptoms, and gut microbiome composition in patients with PWS.Methods: Ethical Approval was issued by the Internal Review Board (IRB) of the Second Affiliated Hospital of Kunming Medical University (Review-YJ-2016-06). We conducted a 12-week, randomized, double-blind, placebo-controlled trial in 68 patients with Prader-Willi syndrome aged 11 months−16 years (mean = 4.2 years old) who were randomly assigned to receive daily B. lactis-11 probiotics (6 × 1010 CFUs) or a placebo sachet. Weight, height, ASQ-3, ABC, SRS-2, and CGI-I were compared between the two groups at baseline and at 6 and 12 weeks into treatment. Gut microbiome data were analyzed with the QIIME 2 software package, and functional gene analysis was conducted with PICRUSt-2.Results: We found a significant increase in height (mean difference = 2.68 cm, P < 0.05) and improvement in CGI-I (P < 0.05) in the probiotics group compared to the placebo group. No significant change in weight or psychological measures were observed. Probiotic treatment altered the microbiome composition to favor weight loss and gut health and increased the abundance of antioxidant production-related genes.Conclusions: The findings suggest a novel therapeutic potential for Bifidobacterium animalis subsp. lactis probiotics in Prader-Willi syndrome patients, although further investigation is warranted.

Download Full-text